OBJECTIVE: Studies in mice have shown that genetic disruption of monocyte chemotactic protein-1 or its receptor, the C-C chemokine receptor 2 (CCR2), inhibits atherosclerosis, but few data exist in humans to suggest that the monocyte chemotactic protein-1-CCR2 interaction is important in atherogenesis. A common polymorphism in the human CCR2 gene resulting in a substitution of isoleucine for valine (Val64Ile) has been associated with other disease phenotypes in humans. METHODS AND RESULTS: A cohort of first-degree relatives of persons with premature coronary artery disease was recruited and quantitatively phenotyped for the extent of CAC, a marker of coronary atherosclerosis, by using electron beam CT. The extent of CAC was significantly lower in subjects with the CCR2-Ile64 variant (Val/Ile and Ile/Ile genotypes) than in subjects carrying 2 Val64 alleles, even after adjustment for traditional risk factors. CONCLUSIONS: This study provides genetic evidence linking CCR2 with coronary atherosclerosis in humans.
OBJECTIVE: Studies in mice have shown that genetic disruption of monocyte chemotactic protein-1 or its receptor, the C-C chemokine receptor 2 (CCR2), inhibits atherosclerosis, but few data exist in humans to suggest that the monocyte chemotactic protein-1-CCR2 interaction is important in atherogenesis. A common polymorphism in the humanCCR2 gene resulting in a substitution of isoleucine for valine (Val64Ile) has been associated with other disease phenotypes in humans. METHODS AND RESULTS: A cohort of first-degree relatives of persons with premature coronary artery disease was recruited and quantitatively phenotyped for the extent of CAC, a marker of coronary atherosclerosis, by using electron beam CT. The extent of CAC was significantly lower in subjects with the CCR2-Ile64 variant (Val/Ile and Ile/Ile genotypes) than in subjects carrying 2 Val64 alleles, even after adjustment for traditional risk factors. CONCLUSIONS: This study provides genetic evidence linking CCR2 with coronary atherosclerosis in humans.
Authors: Marnie J Wood; Lawrie W Powell; Jeannette L Dixon; V Nathan Subramaniam; Grant A Ramm Journal: World J Gastroenterol Date: 2013-12-28 Impact factor: 5.742
Authors: Pallav Bhatnagar; Xiaochun Lu; Michele K Evans; Thomas A Laveist; Alan B Zonderman; Darryl L Carter; Dan E Arking; Craig A Fletcher Journal: Circ Cardiovasc Genet Date: 2012-07-04
Authors: David H McDermott; Alan M Fong; Qiong Yang; Joan M Sechler; L Adrienne Cupples; Maya N Merrell; Peter W F Wilson; Ralph B D'Agostino; Christopher J O'Donnell; Dhavalkumar D Patel; Philip M Murphy Journal: J Clin Invest Date: 2003-04 Impact factor: 14.808
Authors: Dominiek D G Despriet; Arthur A B Bergen; Joanna E Merriam; Jana Zernant; Gaetano R Barile; R Theodore Smith; Irene A Barbazetto; Simone van Soest; Arne Bakker; Paulus T V M de Jong; Rando Allikmets; Caroline C W Klaver Journal: Invest Ophthalmol Vis Sci Date: 2008-01 Impact factor: 4.799
Authors: Renate B Schnabel; Jens Baumert; Maja Barbalic; Josée Dupuis; Patrick T Ellinor; Peter Durda; Abbas Dehghan; Joshua C Bis; Thomas Illig; Alanna C Morrison; Nancy S Jenny; John F Keaney; Christian Gieger; Cathy Tilley; Jennifer F Yamamoto; Natalie Khuseyinova; Gerardo Heiss; Margaret Doyle; Stefan Blankenberg; Christian Herder; Jeremy D Walston; Yanyan Zhu; Ramachandran S Vasan; Norman Klopp; Eric Boerwinkle; Martin G Larson; Bruce M Psaty; Annette Peters; Christie M Ballantyne; Jacqueline C M Witteman; Ron C Hoogeveen; Emelia J Benjamin; Wolfgang Koenig; Russell P Tracy Journal: Blood Date: 2009-12-29 Impact factor: 22.113
Authors: Patrick F McArdle; Afshin Parsa; Yen-Pei C Chang; Matthew R Weir; Jeffery R O'Connell; Braxton D Mitchell; Alan R Shuldiner Journal: Arthritis Rheum Date: 2008-09